u/louied91

ROSHARON, TX / ACCESS Newswire / December 10, 2025 / Signal Advance, Inc. (OTCID: SIGL) today highlighted its Analog Guard^(®) physics-based post-quantum encryption platform following a fast-track U.S. patent allowance, solidifying the company at the forefront of defenses against emerging quantum-era and AI-enabled cyber threats.

The urgency for post-quantum encryption and quantum-era security continues to accelerate - a reality underscored by recent joint announcements from leading global technology companies outlining plans to build the foundation for networked distributed quantum computing as early as the 2030s. These collaborations aim to combine next-generation quantum processors with advanced quantum networking infrastructure, with a goal of connecting large-scale, fault-tolerant quantum computers capable of running computations across tens to hundreds of thousands of qubits. Such networks could enable trillions of quantum gates, dramatically expanding quantum capabilities and heightening risks to today's digital encryption.

Quantum networking breakthroughs and large-scale collaborations are compressing timelines, making "harvest now, decrypt later" a present danger, and demanding innovative, physics-rooted defenses. Analog Guard^(®)'s nonlinear analog approach uniquely sidesteps computational vulnerabilities, offering forward-compatible resilience for the 2030's quantum era by embedding protection directly into the nonlinear physics of analog signals - resilience that purely computational methods cannot match.

The Company has already filed:

1. A U.S. continuation application to broaden and harden claims around the core Analog Guard^(®) mechanism - the timing-synchronized, analog-key-modulated dynamic carrier mixed with the message signal.
2. A U.S. continuation-in-part (CIP) application that captures newer proprietary circuit embodiments, multi-channel encryption paths, and complete end-to-end analog-domain workflows developed since the parent case.
3. Parallel national-phase patent applications in China, Germany, and India - strategic jurisdictions for semiconductor manufacturing, defense systems, critical infrastructure, and high-volume OEM/ODM integration.

"A 3-month Track One allowance is extraordinarily rare and carries real weight with examiners, investors, and potential strategic partners," said Dr. Chris M. Hymel, Founder and CEO of Signal Advance. "This first patent wasn't the finish line - it was the starting gun. We immediately moved to ring-fence the core invention, pull in the latest product-ready embodiments, and extend protection into the world's most important markets. That is exactly the IP progression pattern that licensees, joint-venture partners, and acquirers look for - especially as breakthroughs in large-scale quantum networking initiative remind us that the clock is ticking on quantum vulnerabilities."

The global cybersecurity market is forecast to grow from $193.73 billion in 2024 to $562.72 billion by 2032 (Fortune Business Insights, June 2025), with post-quantum and AI-resilient solutions commanding increasing urgency and premium valuation. Analog Guard^(®) is believed to be the only publicly traded pure-play platform that protects data through nonlinear analog physics rather than purely computational methods.

Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities.

The upgrade program is focused on advancing the facility toward compliance with Health Canada Drug Establishment Licence (DEL) requirements, a critical regulatory pathway for companies engaged in the manufacturing, packaging, testing, distribution, and commercialization of pharmaceutical products in Canada. These enhancements are expected to support production of products requiring a Drug Identification Number (DIN), a key authorization for prescription and over-the-counter drug sales in regulated markets.

Strategic Move Into Pharmaceutical Manufacturing and Global Drug Markets

The Burlington facility upgrades mark a significant step in Rapid Dose Therapeutics' evolution from a drug delivery innovation company into a pharmaceutical manufacturing and commercialization platform. The initiative is designed to expand the Company's capabilities across oral thin film drug delivery, pharmaceutical production, and global distribution channels, supporting its proprietary QuickStrip™ fast-dissolving oral thin film technology.

QuickStrip™ is engineered to deliver pharmaceuticals, nutraceuticals, cannabinoids, vaccines and nicotine products through rapid absorption via the oral mucosa, offering advantages in bioavailability, onset time, and patient compliance compared to traditional capsules, tablets, injections and inhalation-based delivery systems.

GMP and EU GMP Alignment Supports International Expansion

In parallel, Rapid Dose is upgrading its existing cannabis production clean rooms to align with Good Manufacturing Practice (GMP) and European Union GMP (EU GMP) standards, reinforcing its readiness to participate in the rapidly expanding global medical cannabis and pharmaceutical export markets.

These upgrades are expected to enable:

• Entry into regulated international pharmaceutical markets
• Expansion of medical cannabis exports
• Increased participation in high-growth non-smoking cannabis formats
• Enhanced attractiveness for strategic partnerships and licensing agreements

The Burlington facility is being developed into a dual-purpose centralized manufacturing hub, capable of supporting both pharmaceutical-grade production and cannabis-based product manufacturing, creating operational efficiencies and long-term scalability.

As of the date of this release. no approvals have been obtained and timelines and outcomes are uncertain.

Positioned for Market Opportunities

The expansion aligns with major global market trends, including:

• The global pharmaceutical market, projected to reach approximately $1.7 trillion by 2030
• Canada's top 10 global pharmaceutical market position
• The global medical cannabis market, projected to reach approximately $65.9 billion by 2030

These markets are being driven by rising demand for innovative drug delivery systems, patient-friendly dosing formats, and compliant manufacturing infrastructure.

Building a Scalable Platform for Long-Term Growth

"This upgrade represents a pivotal step in expanding the strategic value of our Burlington facility," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "By aligning our operations with internationally recognized pharmaceutical standards, we are strengthening our ability to pursue high-growth commercial opportunities while scaling the global reach of our QuickStrip™ platform."

Upon completion, the upgraded facility is expected to deliver:

• Expanded pharmaceutical manufacturing capabilities
• Enhanced regulatory readiness (DEL, DIN pathways)
• Improved operational efficiency and scalability
• Stronger positioning for global partnerships and licensing deals